This invention is an apparatus for the formation of occlusions in spaces in the human body, occluding such as thrombi in arteries, veins, aneurysms, vascular malformations and arteriovenous fistulas. In particular, it deals with a one piece assembly having an improved electrolytically erodable link to an occlusive member and further having an incorporated return electrode in the assembly. The occlusion-forming member is introduced to and is intended to remain at the desired occlusion site. The invention also relates to the joint itself. The invention further includes a method for introduction and electrolytic separation of the device.
|
1. A process for forming an occlusion in a body cavity in the presence of ionic body fluids, comprising:
deploying a conductive implant detachably connected to a pusher wire at least partially into a body cavity, said pusher wire being insulated from said implant, said implant forming a return path for current provided to said pusher wire through ionic body fluids, and imposing a current in said pusher wire such that an electrolytically severable joint disposed between said implant and said pusher wire releases said implant from said pusher wire.
5. A process for forming an occlusion in a body cavity in the presence of ionic body fluids, comprising:
deploying an implant at least partially into a body cavity, said implant detachably connected to a composite core wire via an electrolytically erodable junction, said composite core wire having a first conductive member and said implant having a second conductive member in electrical contact with said first conductive member, said junction being electrically insulated from said first conductive member and said second conductive member, said implant forming a return path for current provided to said first conductive member through ionic body fluids, and imposing a current to said junction via said composite core wire such that said junction electrolytically erodes to separate said first conductive member from said second conductive member and release said implant into said body cavity.
14. A process for forming an occlusion in a body cavity in the presence of body fluids, comprising:
deploying an implant at least partially into a body cavity, said implant detachably connected to a composite core wire via an electrolytically erodable junction, said composite core wire having first and second electrically conductive members and a first electrically insulating member, said first electrically insulating member configured to directly contact both said first electrically conductive member and said second electrically conductive member, to electrically insulate them from each other, and to electrically insulate said first electrically conductive member from surrounding body fluids, and applying a potential difference between said first electrically conductive member and said second electrically conductive member such that said junction electrolytically erodes to allow complete physical detachment between said implant and said core wire to release said implant into said body cavity.
9. The process of
10. The process of
11. The process of
12. The process of
13. The process of
15. The process of
19. The process of
20. The process of
|
This application is a continuation of U.S. patent application Ser. No. 09/026,373, entitled Assembly Containing an Electrolytically Severable Joint for Endovascular Embolic Devices, filed Feb. 19, 1998, the entirety of which is hereby incorporated by reference, now U.S. Pat. No. 6,077,260.
This invention is an apparatus for the formation of occlusions in spaces in the human body, occluding such as thrombi in arteries, veins, aneurysms, vascular malformations and arteriovenous fistulas. In particular, it deals with a one piece assembly having an improved electrolytically erodable link to an occlusive member and further having an incorporated return electrode in the assembly. The occlusion-forming member is introduced to and is intended to remain at the desired occlusion site. The invention also relates to the joint itself. The invention further includes a method for introduction and electrolytic separation of the device.
Approximately 25,000 intracranial aneurysms rupture each year in North America. The primary purpose of treatment for a ruptured intracranial aneurysm is to prevent rebleeding. There are a variety of ways to treat ruptured and non-ruptured aneurysms.
Possibly the most widely known of these procedures is an extravascular approach using surgery or microsurgery. This treatment is common with intracranial berry aneurysms. The method comprises a step of clipping the neck of the aneurysm, performing a suture ligation of the neck, or wrapping the entire aneurysm. Each of these procedures is formed by intrusive invasion into the body and performed from the outside of the aneurysm or target site. General anesthesia, craniotomy, brain retraction, and placement of a clip around the neck of the aneurysm are typically required in these surgical procedures. The surgical procedure is often delayed while waiting for the patient to stabilize medically. For this reason, many patients die from the underlying disease or defect prior to the initiation of the procedure.
Another procedure--the extra-intravascular approach--involves surgically exposing or stereotactically reaching an aneurysm with a probe. The wall of the aneurysm is then perforated from the outside and various techniques are used to occlude the interior in order to prevent it from rebleeding. The techniques used to occlude the aneurysm include electrothrombosis, adhesive embolization, hog hair embolization, and ferromagnetic thrombosis. These procedures are discussed in U.S. Pat. No. 5,122,136 to Guglielmi et al., the entirety of which is incorporated by reference.
A still further approach is the least invasive and is additionally described in Guglielmi et al. It is the endovascular approach. In this approach, the interior of the aneurysm is entered by use of a catheter such as those shown in U.S. Pat. Nos. 4,884,575 and U.S. Pat. No. 4,739,768, both to Engelson. These patents describe devices utilizing core wires and catheters, respectively, which allow access to the aneurysm from remote portions of the body. By the use of catheters having very flexible distal regions and core wires which are steerable to the region of the aneurysm, embolic devices which may be delivered through the catheter are an alternative to the extravascular and extra-intravascular approaches.
The endovascular approach typically includes two major steps. The first step involves the introduction of the catheter to the aneurysm site using catheters such as shown in the Engelson patents. The second step often involves filling the aneurysm in some fashion or another. For instance, a balloon may be introduced into the aneurysm from the distal portion of the catheter where it is inflated, detached, and left to occlude the aneurysm. In this way, the parent artery is preserved. Balloons are becoming less favorable because of the difficulty in introducing the balloon into the aneurysm sac, the possibility of an aneurysm rupture due to overinflation of the balloon within the aneurysm, and the risk associated with the traction produced when detaching the balloon.
A highly desirable embolism-forming device which may be introduced into an aneurysm using endovascular placement procedures is found in U.S. Pat. No. 4,994,069, to Ritchart et al. The device, typically a platinum/tungsten alloy coil having a very small diameter, may be introduced into an aneurysm through a catheter such as those described in Engelson above. These coils are often made of wire having a diameter of 2-6 mils. The coil diameter may be 10-30 mils. These soft, flexible coils may be of any length desirable and appropriate for the site to be occluded. For instance, the coils may be used to fill a berry aneurysm. Within a short period of time after the filling of the aneurysm with the embolic device, a thrombus forms in the aneurysm and is shortly thereafter complemented with a collagenous material which significantly lessens the potential for aneurysm rupture. Coils such as seen in Ritchart et al. may be delivered to the vasculature site in a variety of ways including, e.g., mechanically detaching them from the delivery device as is shown in U.S. Pat. No. 5,250,071, to Palermo or by electrolytic detachment as is shown in Guglielmi et al. (U.S. Pat. No. 5,122,136) as discussed above.
Guglielmi et al. teaches an embolism-forming device and procedure for using that device. Specifically, Guglielmi et al. fills a vascular cavity such as an aneurysm with an embolic device such as a platinum coil which has been endovascularly delivered. The coil is then severed from its insertion tool by the application of a small electric current. Desirably, the insertion device involves a core wire which is attached at its distal end to an embolic device by an electrolytic, sacrificial joint. Guglielmi et al. suggests that when the embolic device is a platinum coil, the coil may have a length ranging from 1 cm to 50 cm or longer as is necessary. Proximal of the embolic coil is an insulated core wire or pusher wire, often stainless steel in construction. The core wire is used to push the platinum embolic coil, obviously with great gentleness, into the vascular site to be occluded. The Guglielmi et al. patent shows a variety of ways to link the embolic coil to the core wire. For instance, the core wire is tapered at its distal end and the distal tip of the core wire is welded into the proximal end of the embolic coil. Additionally, a stainless steel coil is wrapped coaxially about the distal tapered portion of the core wire to provide column strength to the core wire. This coaxial stainless steel wire is joined both to the core wire and to the embolic coil. Insulation may be used to cover a portion of the strength-providing stainless steel coil. This arrangement provides for two regions which must be electrolytically severed before the embolic coil is severed from the core wire.
A still further variation found in Guglielmi et al. includes a thin, threadlike extension between the core wire core and the proximal end of the embolic coil. In this way, the core wire does not extend to the embolic coil, but instead relies upon a separately introduced extension.
A continuation-in-part of the Guglielmi et al. patent discussed above, U.S. Pat. No. 5,354,295, describes the use of mechanically detachable embolic devices as well as those which are electrolytically detachable. The embolic devices may be augmented with attached filaments. U.S. Pat. No. 5,540,680, a continuation of U.S. Pat. No. 5,354,295, further describes such mechanically and electrolytically detachable embolic devices. U.S. Pat. No. 5,569,245, a continuation-in-part of the U.S. Pat. No. 5,540,680 patent, adds several new aspects including a new method for electrocoagulation.
A further variation of the Guglielmi et al. device is one in which the distal tip of the stainless steel core wire is crimped onto the proximal end of the embolic device. A simple tapered stainless steel wire extends from the stainless steel pusher wire to the embolic coil.
Taki et al. have devised a variation of the Guglielmi detachable coil using a copper link between the core wire and the coil, described in Treatment of a Spontaneous Carotid Cavernous Fistula Using an Electrodetachable Microcoil, American Journal of Neuroradiology, Vol. 14 (1993).
U.S. Pat. Nos. 5,423,829 to Pham et al. and U.S. Pat. No. 5,624,449 to Pham et al. describe an electrolytically detachable vaso-occlusive device containing a discrete sacrificial link between the core wire and the vaso-occlusive device to allow clean and quick detachment from the core wire, reducing the possibility of multiple electrolysis sites. The use of extensive electrical insulation about the core wire and sacrificial link as well as the use of scoring on the insulation to focus electrolysis on a targeted, specific site on the link is also taught by Pham et al.
None of the noted procedures using electrolytically detachable embolic devices suggest the structure of the erodable link and related composite core wire described herein.
This invention is a device for forming an occlusion in the human body. Particularly, it is for forming a vascular occlusion. Generally, the device comprises a core wire having a distal tip, which distal tip may be introduced into the selected vascular site or cavity. The core wire is joined to the distal tip or embolic device in such a way that the vascular device may be electrolytically detached by application of a current to the core wire. The improvement involves the use of a discrete, erodable link between the composite core wire and the vascular implant device to allow clean and quick detachment from the composite core wire and the placement of the return electrode at the inventive assembly. Specifically the most desirable of the improved sacrificial joints is a narrow band which has been cut from a coating, e.g., a polymeric coating adherent to the metallic substrate, perhaps by laser cutting. Focused electrolysis produced at the erodable site as a result of a key improvement, two independent conductive layers within the composite core wire, increases electrolysis precision and efficiency by eliminating the need for a charged extracutaneous patch. This focused electrolysis also reduces the overall possibility of occurrence of multiple electrolysis sites and liberation of large particles from those sites. Further, placement of the return electrode of the inventive assembly removes the necessity of the prior art devices to place a return electrode on the skin of the patient and instead places the return electrode next to the erodable sacrificial joint in the body's ionic fluids.
This invention involves an assembly having a pusher, an electrolytically erodible joint, a distally located occlusion device, and a return electrode. These are two major variations of this inventive device. The first, discussed just below, utilizes the occlusion device as the return electrode. The second variation utilizes a specifically placed return electrode on the outer surface of the pusher.
In this variation, the composite core wire (100) comprises several elements. A first electrically conductive member (102) extends from the proximal end to the distal end of the core wire (100), and is capable of carrying electric current. This member (102) may comprise a tubular, multistrand, or braided structure. Preferably, conductive member (102) comprises a small electric wire lead running along the longitudinal axis of the core wire (100), as is shown in
In the variations depicted in
Also shown in
Highly desirable is the variation, depicted in
Alternatively, as depicted in
Further, as depicted in
Also depicted in
The proximal portion of the third electrically conductive member (202) is configured to establish electrical contact with the first electrically conductive member (102) when the implant (200) and core wire (100) are urged together, while it is also configured to easily relinquish such electrical contact when the junction (300) between the implant (200) and the core wire (100) is eroded, thus allowing the implant (200) and core wire (100) to move apart.
As discussed in passing above, electrolytically erodable junction (300) between the implant (200) and composite core wire (100) is also shown in
Preferably, the electrically conductive erodable ring (306) has a narrow range of circumferential contact with surrounding body fluids, so that erosion will be focused. By "focused" we mean that erosion will be limited to a narrow circumferential band, rather than a broad one; this will result in quicker erosion through the thickness of the electrically conductive erodable ring (306). In the preferred variation, a ring insulating outer layer (308) may be disposed around the erodable ring (306) in a configuration that would electrically isolate it from surrounding body fluids; this ring insulating outer layer (308) may then be scored or cut to produce a very narrow circumferential band (312) exposing the ring (306) to surrounding body fluids. The scoring may be made physically using a sharp object, abrasive spray techniques, or more preferably, may be done with a laser or like focused energy source.
Because the electrically conductive erodable ring (306) is in electrical contact with body fluids and the second electrically conductive member (104), it assumes a positive charge in an ionic medium. Since the exposed area (206) is in contact with body fluids and the third electrically conductive member (202), which is itself in contact with the first electrically conductive member (102), the exposed area (206) assumes a negative charge in an ionic medium. In the preferred variation, the electrically conductive erodable ring (306) is comprised of a metal less noble that that which comprises the exposed area (206) of the implant. Given these conditions, galvanic corrosion of the electrically conductive erodable ring (306) occurs and the ring material is eroded away, as shown in FIG. 6B. When the entire thickness of the ring (306) has been eroded, the implant (200) will no longer be physically constrained to the core wire (100), and the core wire (100) can be pulled away, breaking contact between the first electrically conductive member (102) and the third electrically conductive member (202), as shown in FIG. 6C. The core wire (100) and delivery catheter (500) can then be fully withdrawn, leaving the deployed implant (200).
The second electrically conductive member (708) of this variation may be a tubular member or coating which surrounds the first electrically insulating member (710). More preferably, the second electrically conductive member (708) comprises a single electrical lead extending along one aspect of the generally tubular first electrically insulating member (710) from the proximal end of the core wire (700) to the distal end, wherein the second electrically conductive member (708) is configured to form a loop (714) around the distal end of the first electrically insulating member (710). The single electrical lead configuration, depicted in
In this variation, the implant (704) is held in position at the distal end of the wire assembly by an electrolytically erodable junction (702), as shown in FIG. 3. This junction (702) generally comprises an electrically conductive member which is in direct electrical contact with the surrounding body fluids and the first electrically conductive member (706), is structurally connected to the implant (704), and is electrically insulated from the second electrically conductive member (708) of the core wire (700). The electrolytically erodable junction (702) typically comprises an extension of the first electrically conductive member (706) and the first electrically insulating member (710), with a score or cut through the insulating member to expose a narrow band (718) of the conductive member to surrounding body fluids. This narrow circumferential band of body fluid exposure is desirable for focused erosion as described above.
Since the narrow circumferential band (718) of the distal extension of the first electrically conductive member (102) is in electrical contact with body fluids around that circumferential band (718), it assumes a positive charge in an ionic medium. The second electrically conductive member (708) assumes a negative charge in an ionic medium. In the preferred variation, the first electrically conductive member (706) is comprised of a metal less noble that that which comprises the second electrically conductive member (708). Given these conditions, galvanic corrosion of the first electrically conductive member (706) occurs at the circumferential region (718) of body fluid contact, and the conductive material is eroded away as shown in FIG. 7B.
The material comprising the implant (704) in the preferred variation will not erode due either to an implant insulating layer (724) being in place to electrically insulate the proximal end of the implant (704) from surrounding body fluids, as shown in
The materials used for the various electrically insulating members and layers discussed herein may be flexible polymeric coatings or layers such as polyfluorocarbons, polyurethane, polyethylene, polypropylene, polyimides, silicone polymers, or other suitable polymeric materials. Such polymeric materials are generally flexible, have good electrical insulation properties, and are amenable to sharp edge or laser scoring. The implant (704) may be a biocompatible metal or polymer but generally is comprised of a metal such as platinum or nickel-titanium, or alloys thereof.
Many alterations and modifications may be made by those having ordinary skill in the art without departing from the spirit and scope of the invention. The illustrated variations have been used only for the purposes of clarity and should not be taken as limiting the invention as defined by the following claims.
Engelson, Erik T., Carrison, Harold F., Wheelock, E. Thomas
Patent | Priority | Assignee | Title |
10028747, | May 01 2008 | Aneuclose LLC | Coils with a series of proximally-and-distally-connected loops for occluding a cerebral aneurysm |
10070866, | Aug 01 2013 | AVE; AVENU MEDICAL, INC | Percutaneous arterial to venous anastomosis clip application catheter system and methods |
10076399, | Sep 13 2013 | Covidien LP | Endovascular device engagement |
10124087, | Jun 19 2012 | Covidien LP | Detachable coupling for catheter |
10231722, | Jan 20 2015 | NEUROGAMI MEDICAL, INC | Micrograft for the treatment of intracranial aneurysms and method for use |
10231771, | Feb 08 2012 | Avenu Medical, Inc. | Intravascular arterial to venous anastomosis and tissue welding catheter |
10285678, | Jan 20 2015 | NEUROGAMI MEDICAL, INC | Micrograft for the treatment of intracranial aneurysms and method for use |
10285679, | Jan 20 2015 | NEUROGAMI MEDICAL, INC | Micrograft for the treatment of intracranial aneurysms and method for use |
10299775, | Jan 20 2015 | NEUROGAMI MEDICAL, INC | Micrograft for the treatment of intracranial aneurysms and method for use |
10335155, | Nov 30 2011 | Covidien LP | Positioning and detaching implants |
10342683, | Jul 19 2002 | USSC MEDICAL GMBH | Medical implant having a curlable matrix structure and method of use |
10413310, | Oct 17 2007 | Covidien LP | Restoring blood flow and clot removal during acute ischemic stroke |
10420563, | Jul 08 2016 | NEUROGAMI MEDICAL, INC | Delivery system insertable through body lumen |
10426644, | Oct 01 2010 | Covidien LP | Methods and apparatuses for flow restoration and implanting members in the human body |
10456151, | Feb 22 2008 | Covidien LP | Methods and apparatus for flow restoration |
10499919, | Aug 21 2015 | AVENU MEDICAL, INC | Systems and methods for percutaneous access and formation of arteriovenous fistulas |
10512469, | Aug 19 2008 | Covidien LP | Detachable tip microcatheter |
10537333, | Mar 14 2013 | STRYKER EUROPEAN HOLDINGS III, LLC | Vaso-occlusive device delivery system |
10575839, | Jul 29 2014 | University of Kansas | Solenoid occlusion device |
10653403, | Jan 20 2015 | NEUROGAMI MEDICAL, INC | Micrograft for the treatment of intracranial aneurysms and method for use |
10695065, | Aug 01 2013 | Avenu Medical, Inc. | Percutaneous arterial to venous anastomosis clip application catheter system and methods |
10716573, | May 01 2008 | Aneuclose LLC | Janjua aneurysm net with a resilient neck-bridging portion for occluding a cerebral aneurysm |
10722255, | Dec 23 2008 | Covidien LP | Systems and methods for removing obstructive matter from body lumens and treating vascular defects |
10722285, | Nov 14 2012 | Avenu Medical, Inc. | Intravascular arterial to venous anastomosis and tissue welding catheter |
10736730, | Jan 20 2015 | NEUROGAMI MEDICAL, INC | Vascular implant |
10751461, | Jun 15 2010 | Avenu Medical, Inc. | Systems and methods for creating arteriovenous (AV) fistulas |
10772672, | Mar 06 2014 | AVENU MEDICAL, INC | Systems and methods for percutaneous access and formation of arteriovenous fistulas |
10799225, | Jan 20 2015 | NEUROGAMI MEDICAL, INC | Micrograft for the treatment of intracranial aneurysms and method for use |
10828037, | Jun 27 2016 | Covidien LP | Electrolytic detachment with fluid electrical connection |
10828039, | Jun 27 2016 | Covidien LP | Electrolytic detachment for implantable devices |
10857012, | Jan 20 2015 | NEUROGAMI MEDICAL, INC | Vascular implant |
10874401, | Aug 08 2014 | Covidien LP | Electrolytic and mechanical detachment for implant delivery systems |
10893868, | Jan 20 2012 | Covidien LP | Aneurysm treatment coils |
10925611, | Jan 20 2015 | NEUROGAMI MEDICAL, INC | Packaging for surgical implant |
11006940, | Jan 20 2015 | Neurogami Medical, Inc. | Micrograft for the treatment of intracranial aneurysms and method for use |
11006963, | Sep 03 2013 | Detachment mechanisms for implantable devices | |
11051822, | Jun 28 2016 | Covidien LP | Implant detachment with thermal activation |
11096679, | Jan 20 2015 | Neurogami Medical, Inc. | Micrograft for the treatment of intracranial aneurysms and method for use |
11166727, | Aug 21 2015 | Avenu Medical, Inc. | Systems and methods for percutaneous access and formation of arteriovenous fistulas |
11172976, | Feb 08 2012 | Avenu Medical, Inc. | Intravascular arterial to venous anastomosis and tissue welding catheter |
11241223, | Jan 20 2015 | Neurogami Medical, Inc. | Micrograft for the treatment of intracranial aneurysms and method for use |
11304712, | Sep 13 2013 | Covidien LP | Endovascular device engagement |
11337714, | Oct 17 2007 | Covidien LP | Restoring blood flow and clot removal during acute ischemic stroke |
11426293, | Jul 19 2002 | USSC MEDICAL GMBH | Medical implant |
11457927, | Aug 19 2008 | Covidien LP | Detachable tip microcatheter |
11457970, | Nov 14 2012 | Avenu Medical, Inc. | Intravascular arterial to venous anastomosis and tissue welding catheter |
11484319, | Jan 20 2015 | NEUROGAMI MEDICAL, INC | Delivery system for micrograft for treating intracranial aneurysms |
11529156, | Feb 22 2008 | Covidien LP | Methods and apparatus for flow restoration |
11622772, | Mar 14 2013 | STRYKER EUROPEAN HOLDINGS III, LLC | Vaso-occlusive device delivery system |
11627950, | Jan 20 2015 | Neurogami Medical, Inc. | Micrograft for the treatment of intracranial aneurysms and method for use |
11653923, | Aug 01 2013 | Avenu Medical, Inc. | Percutaneous arterial to venous anastomosis clip application catheter system and methods |
11690944, | Jun 15 2010 | Avenu Medical, Inc. | Systems and methods for creating arteriovenous (AV) fistulas |
11779452, | Jan 20 2015 | NEUROGAMI MEDICAL, INC | Vascular implant |
11786255, | Jan 20 2015 | NEUROGAMI MEDICAL, INC | Packaging for surgical implant |
11839380, | Aug 08 2014 | Covidien LP | Electrolytic and mechanical detachment for implant delivery systems |
11877785, | Mar 06 2014 | Avenu Medical, Inc. | Systems and methods for percutaneous access and formation of arteriovenous fistulas |
6589236, | Feb 19 1998 | STRYKER EUROPEAN HOLDINGS III, LLC | Assembly containing an electrolytically severable joint for endovascular embolic devices |
6605101, | Sep 26 2000 | MicroVention, Inc.; MICROVENTION, INC | Microcoil vaso-occlusive device with multi-axis secondary configuration |
7410482, | Sep 04 1998 | STRYKER EUROPEAN HOLDINGS III, LLC | Detachable aneurysm neck bridge |
7744583, | Feb 03 2003 | STRYKER EUROPEAN HOLDINGS III, LLC | Systems and methods of de-endothelialization |
7763077, | Dec 24 2003 | BIOMERIX CORPORATION, THE | Repair of spinal annular defects and annulo-nucleoplasty regeneration |
7803395, | May 15 2003 | DSM IP ASSETS B V | Reticulated elastomeric matrices, their manufacture and use in implantable devices |
7976527, | Oct 17 1997 | Covidien LP | Device and method for controlling injection of liquid embolic composition |
8002789, | May 31 2005 | STRYKER EUROPEAN HOLDINGS III, LLC | Stretch-resistant vaso-occlusive devices with flexible detachment junctions |
8048104, | Aug 27 2002 | Dendron GmbH | Device for the implantation of occlusion spirals |
8202292, | Oct 13 2008 | STRYKER EUROPEAN HOLDINGS III, LLC | Vaso-occlusive coil delivery system |
8221483, | May 18 2007 | STRYKER EUROPEAN HOLDINGS III, LLC | Medical implant detachment systems and methods |
8328860, | Mar 13 2007 | Covidien LP | Implant including a coil and a stretch-resistant member |
8398671, | Apr 16 2009 | STRYKER EUROPEAN HOLDINGS III, LLC | Electrical contact for occlusive device delivery system |
8454649, | Oct 17 1997 | Covidien LP | Device and method for controlling injection of liquid embolic composition |
8597321, | Oct 30 1999 | Covidien LP | Device for the implantation of occlusion spirals |
8632584, | Jul 19 2002 | USSC MEDICAL GMBH | Medical implant having a curlable matrix structure and method of use |
8679142, | Feb 22 2008 | Covidien LP | Methods and apparatus for flow restoration |
8771294, | Nov 26 2004 | BIOMETRIX CORPORATION; Biomerix Corporation | Aneurysm treatment devices and methods |
8777978, | Apr 17 2006 | Covidien LP | System and method for mechanically positioning intravascular implants |
8777979, | Apr 17 2006 | Covidien LP | System and method for mechanically positioning intravascular implants |
8795320, | Apr 17 2006 | Covidien LP | System and method for mechanically positioning intravascular implants |
8795321, | Apr 17 2006 | Covidien LP | System and method for mechanically positioning intravascular implants |
8801747, | Mar 13 2007 | Covidien LP | Implant, a mandrel, and a method of forming an implant |
8864790, | Apr 17 2006 | Covidien LP | System and method for mechanically positioning intravascular implants |
8940003, | Feb 22 2008 | Covidien LP | Methods and apparatus for flow restoration |
8940011, | Sep 09 2008 | Boston Scientific Scimed, Inc. | Composite detachment mechanisms |
8974513, | May 18 2007 | STRYKER EUROPEAN HOLDINGS III, LLC | Medical implant detachment systems and methods |
9011480, | Jan 20 2012 | Covidien LP | Aneurysm treatment coils |
9039749, | Oct 01 2010 | Covidien LP | Methods and apparatuses for flow restoration and implanting members in the human body |
9050095, | Sep 22 2004 | Covidien LP | Medical implant |
9131941, | Jun 17 2011 | CURASEAL INC | Fistula treatment devices and methods |
9161766, | Feb 22 2008 | Covidien LP | Methods and apparatus for flow restoration |
9198665, | Sep 22 2004 | Covidien LP | Micro-spiral implantation device |
9211116, | Jun 16 2011 | CURASEAL INC | Fistula treatment devices and related methods |
9254134, | Jan 21 2004 | Dendron GmbH | Device for implanting electrically isolated occlusion helixes |
9265504, | Oct 13 2008 | STRYKER EUROPEAN HOLDINGS III, LLC | Vaso-occlusive coil delivery system |
9289215, | Mar 13 2007 | Covidien LP | Implant including a coil and a stretch-resistant member |
9314250, | Apr 16 2009 | STRYKER EUROPEAN HOLDINGS III, LLC | Electrical contact for occlusive device delivery system |
9326774, | Aug 03 2012 | Covidien LP | Device for implantation of medical devices |
9358014, | Oct 17 1997 | Covidien LP | Device and method for controlling injection of liquid embolic composition |
9358140, | Nov 18 2009 | Aneuclose LLC | Stent with outer member to embolize an aneurysm |
9439710, | Nov 14 2012 | AVENU MEDICAL, INC | Intravascular arterial to venous anastomosis and tissue welding catheter |
9445868, | Jun 15 2010 | AVENU MEDICAL, INC | Systems and methods for creating arteriovenous (AV) fistulas |
9452015, | Jun 15 2010 | AVENU MEDICAL, INC | Intravascular arterial to venous anastomosis and tissue welding catheter |
9468739, | Aug 19 2008 | Covidien LP | Detachable tip microcatheter |
9474562, | Feb 08 2012 | AVENU MEDICAL, INC | Intravascular arterial to venous anastomosis and tissue welding catheter |
9486608, | Aug 19 2008 | Covidien LP | Detachable tip microcatheter |
9504475, | Apr 06 2009 | STRYKER EUROPEAN HOLDINGS III, LLC | Delivery wire for occlusive device delivery system |
9579104, | Nov 30 2011 | Covidien LP | Positioning and detaching implants |
9687245, | Mar 23 2012 | Covidien LP | Occlusive devices and methods of use |
9713475, | Apr 18 2014 | Covidien LP | Embolic medical devices |
9717502, | Mar 14 2013 | STRYKER EUROPEAN HOLDINGS III, LLC | Vaso-occlusive device delivery system |
9717503, | May 11 2015 | Covidien LP | Electrolytic detachment for implant delivery systems |
9775620, | Sep 09 2008 | Boston Scientific Scimed, Inc | Composite detachment mechanisms |
9808256, | Aug 08 2014 | Covidien LP | Electrolytic detachment elements for implant delivery systems |
9814466, | Aug 08 2014 | Covidien LP | Electrolytic and mechanical detachment for implant delivery systems |
9931164, | Jun 15 2010 | Avenu Medical, Inc.; Baja Research, LLC | Intravascular arterial to venous anastomosis and tissue welding catheter |
9962146, | Jan 20 2015 | NEUROGAMI MEDICAL, INC | Micrograft for the treatment of intracranial aneurysms and method for use |
9993235, | Sep 04 2008 | Curaseal Inc. | Enteric fistula treatment devices |
9999413, | Jan 20 2015 | NEUROGAMI MEDICAL, INC | Micrograft for the treatment of intracranial aneurysms and method for use |
Patent | Priority | Assignee | Title |
4739768, | Jun 02 1986 | STRYKER EUROPEAN HOLDINGS III, LLC | Catheter for guide-wire tracking |
4884575, | Dec 08 1987 | Intermedics, Inc. | Cardiac pacer with patient-controlled exercise rate and method |
4994069, | Nov 02 1988 | STRYKER EUROPEAN HOLDINGS III, LLC | Vaso-occlusion coil and method |
5122136, | Mar 13 1990 | BLOSSOM FLOWER INC | Endovascular electrolytically detachable guidewire tip for the electroformation of thrombus in arteries, veins, aneurysms, vascular malformations and arteriovenous fistulas |
5250071, | Sep 22 1992 | TARGET THERAPEUTICS, A DELAWARE CORPORATION | Detachable embolic coil assembly using interlocking clasps and method of use |
5354295, | Mar 13 1990 | STRYKER EUROPEAN HOLDINGS III, LLC | In an endovascular electrolytically detachable wire and tip for the formation of thrombus in arteries, veins, aneurysms, vascular malformations and arteriovenous fistulas |
5423829, | Nov 03 1993 | STRYKER EUROPEAN HOLDINGS III, LLC | Electrolytically severable joint for endovascular embolic devices |
5522836, | Jun 27 1994 | STRYKER EUROPEAN HOLDINGS III, LLC | Electrolytically severable coil assembly with movable detachment point |
5540680, | Mar 13 1990 | STRYKER EUROPEAN HOLDINGS III, LLC | Endovascular electrolytically detachable wire and tip for the formation of thrombus in arteries, veins, aneurysms, vascular malformations and arteriovenous fistulas |
5549624, | Jun 24 1994 | Target Therapeutics, Inc | Fibered vasooclusion coils |
5569245, | Mar 13 1990 | The Regents of the University of California | Detachable endovascular occlusion device activated by alternating electric current |
5582619, | Jun 30 1995 | STRYKER EUROPEAN HOLDINGS III, LLC | Stretch resistant vaso-occlusive coils |
5601600, | Sep 08 1995 | Bayer HealthCare LLC | Endoluminal coil delivery system having a mechanical release mechanism |
5624449, | Nov 03 1993 | STRYKER EUROPEAN HOLDINGS III, LLC | Electrolytically severable joint for endovascular embolic devices |
5624461, | Jun 06 1995 | STRYKER EUROPEAN HOLDINGS III, LLC | Three dimensional in-filling vaso-occlusive coils |
5634942, | Apr 21 1994 | B. Braun Celsa | Assembly comprising a blood filter for temporary or definitive use and a device for implanting it |
5643254, | Mar 03 1994 | STRYKER EUROPEAN HOLDINGS III, LLC | Endovascular embolic device detachment detection method |
5645082, | Jan 29 1993 | SICHUAN JINJIANG ELECTRONIC SCIENCE AND TECHNOLOGY CO , LTD | Intravascular method and system for treating arrhythmia |
5645558, | Apr 20 1995 | Micrus Corporation | Anatomically shaped vasoocclusive device and method of making the same |
5669905, | Mar 03 1994 | STRYKER EUROPEAN HOLDINGS III, LLC | Endovascular embolic device detachment detection method and apparatus |
5733294, | Feb 28 1996 | Scion Medical Limited | Self expanding cardiovascular occlusion device, method of using and method of making the same |
5743905, | Jul 07 1995 | Regents of the University of California, The; Target Therapeutics, Inc | Partially insulated occlusion device |
5800454, | Mar 17 1997 | PRECISION VASCULAR SYSTEMS, INC | Catheter deliverable coiled wire thromboginic apparatus and method |
5855578, | Mar 13 1990 | Regents of the University of California, The | Endovascular electrolytically detachable wire and tip for the formation of thrombus in arteries, veins, aneurysms, vascular malformations and arteriovenous fistulas |
5891128, | Dec 30 1994 | STRYKER EUROPEAN HOLDINGS III, LLC | Solderless electrolytically severable joint for detachable devices placed within the mammalian body |
5891130, | Nov 13 1992 | Target Therapeutics, Inc. | Axially detachable embolic coil assembly |
5895385, | Mar 13 1990 | The Regents of the University of California | Endovascular electrolytically detachable wire and tip for the formation of thrombus in arteries, veins, aneurysms, vascular malformations and arteriovenous fistulas |
5895391, | Sep 27 1996 | Target Therapeutics, Inc | Ball lock joint and introducer for vaso-occlusive member |
5911717, | Mar 17 1997 | PRECISION VASCULAR SYSTEMS, INC | Catheter deliverable thrombogenic apparatus and method |
5916235, | Aug 13 1997 | The Regents of the University of California | Apparatus and method for the use of detachable coils in vascular aneurysms and body cavities |
5919187, | Mar 13 1990 | The Regents of the University of California | Method and apparatus for endovascular thermal thrombosis and thermal cancer treatment |
5925037, | Mar 13 1990 | The Regents of the University of California | Endovascular electrolytically detachable wire and tip for the formation of thrombus in arteries, veins, aneurysms, vascular malformations and arteriovenous fistulas |
5925062, | Sep 02 1992 | Board of Regents, The University of Texas System | Intravascular device |
5928226, | Mar 13 1990 | The Regents of the University of California | Endovascular electrolytically detachable wire and tip for the formation of thrombus in arteries, veins, aneurysms, vascular malformations and arteriovenous fistulas |
5944714, | Mar 13 1990 | The Regents of the University of California | Endovascular electrolytically detachable wire and tip for the formation of thrombus in arteries, veins, aneurysms, vascular malformations and arteriovenous fistulas |
5984929, | Aug 29 1997 | STRYKER EUROPEAN HOLDINGS III, LLC | Fast detaching electronically isolated implant |
WO9748351, | |||
WO9802100, | |||
WO9804198, | |||
WO9804315, |
Executed on | Assignor | Assignee | Conveyance | Frame | Reel | Doc |
Mar 10 2000 | Target Therapeutics, Inc. | (assignment on the face of the patent) | / | |||
Jan 03 2011 | Target Therapeutics, Inc | Stryker Corporation | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 025957 | /0313 | |
Jan 03 2011 | Target Therapeutics, Inc | Stryker NV Operations Limited | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 025957 | /0313 | |
Oct 13 2015 | Stryker NV Operations Limited | STRYKER MEDTECH LIMITED | CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECT SERIAL # 09 905,670 AND 07 092,079 PREVIOUSLY RECORDED AT REEL: 037153 FRAME: 0034 ASSIGNOR S HEREBY CONFIRMS THE NUNC PRO TUNC ASSIGNMENT | 038039 | /0001 | |
Oct 13 2015 | STRYKER MEDTECH LIMITED | STRYKER EUROPEAN HOLDINGS I, LLC | CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECT LISTED SERIAL NOS 09 905,670 AND 07 092,079 PREVIOUSLY RECORDED AT REEL: 037153 FRAME: 0241 ASSIGNOR S HEREBY CONFIRMS THE NUNC PRO TUNC ASSIGNMENT EFFECTIVE DATE 9 29 2014 | 038043 | /0011 | |
Oct 13 2015 | Stryker NV Operations Limited | STRYKER MEDTECH LIMITED | NUNC PRO TUNC ASSIGNMENT SEE DOCUMENT FOR DETAILS | 037153 | /0034 | |
Oct 13 2015 | STRYKER MEDTECH LIMITED | STRYKER EUROPEAN HOLDINGS I, LLC | NUNC PRO TUNC ASSIGNMENT SEE DOCUMENT FOR DETAILS | 037153 | /0241 | |
Feb 26 2019 | STRYKER EUROPEAN HOLDINGS III, LLC | Stryker European Operations Holdings LLC | CHANGE OF NAME SEE DOCUMENT FOR DETAILS | 052860 | /0716 | |
May 19 2020 | STRYKER EUROPEAN HOLDINGS I, LLC | STRYKER EUROPEAN HOLDINGS III, LLC | NUNC PRO TUNC ASSIGNMENT SEE DOCUMENT FOR DETAILS | 052861 | /0001 |
Date | Maintenance Fee Events |
Nov 23 2005 | M1551: Payment of Maintenance Fee, 4th Year, Large Entity. |
Jan 27 2006 | ASPN: Payor Number Assigned. |
Nov 20 2009 | M1552: Payment of Maintenance Fee, 8th Year, Large Entity. |
May 12 2011 | ASPN: Payor Number Assigned. |
May 12 2011 | RMPN: Payer Number De-assigned. |
Jan 31 2014 | REM: Maintenance Fee Reminder Mailed. |
Jun 25 2014 | EXP: Patent Expired for Failure to Pay Maintenance Fees. |
Date | Maintenance Schedule |
Jun 25 2005 | 4 years fee payment window open |
Dec 25 2005 | 6 months grace period start (w surcharge) |
Jun 25 2006 | patent expiry (for year 4) |
Jun 25 2008 | 2 years to revive unintentionally abandoned end. (for year 4) |
Jun 25 2009 | 8 years fee payment window open |
Dec 25 2009 | 6 months grace period start (w surcharge) |
Jun 25 2010 | patent expiry (for year 8) |
Jun 25 2012 | 2 years to revive unintentionally abandoned end. (for year 8) |
Jun 25 2013 | 12 years fee payment window open |
Dec 25 2013 | 6 months grace period start (w surcharge) |
Jun 25 2014 | patent expiry (for year 12) |
Jun 25 2016 | 2 years to revive unintentionally abandoned end. (for year 12) |